Retatrutide Receptors

Retatrutide targets three class B G-protein-coupled receptors: GIP, GLP-1 and glucagon. This page is the entry point to the receptor silo and links to the dedicated page for each one.

Last editorial review: 2026-09-18 · Part of the Retatrutide research hub · Mechanism & Receptor Science

The three targets at a glance

All three receptors retatrutide engages belong to the class B secretin-like GPCR family, and all three couple primarily to Gs, raising intracellular cAMP. What differs between them is tissue distribution and the physiological direction of the signal they carry.

That shared signalling route with different tissue emphasis is what makes a single peptide able to act on several arms of metabolism at once, and what makes the potency ratio between the three the governing design variable.

Why three and not one

Single-receptor agonists ask one pharmacological question. A poly-agonist asks several simultaneously, and the answer depends on how the activities are weighted. This is why the published characterisation of retatrutide reports a separate potency at each receptor rather than a single number.

It also shapes experimental design: any conclusion attributing an observation to one receptor arm requires either a receptor-selective comparator or a system that does not express the other two.

What is not established

The receptor targets are documented. The optimal balance between them for any specific endpoint is not, and neither is the individual contribution of each arm in an intact system. Retatrutide remains an investigational compound supplied here strictly for laboratory research.

Signalling mechanics shared by the three receptors

All three receptors couple through Gαs to adenylate cyclase, raising cyclic AMP as the shared proximal signal, and all three are subject to beta-arrestin recruitment and internalisation following sustained agonist exposure. These shared mechanics mean that generic GPCR pharmacology methods — cAMP assays, arrestin recruitment assays, radioligand or fluorescent binding assays — apply across the set, with the receptor construct as the main variable between experiments.

Where the receptors differ is not the proximal signalling route but the downstream tissue context: the same cAMP rise means something different in a hepatocyte than in an islet beta cell, because the downstream transcriptional and metabolic machinery differs by tissue.

Assay design for a poly-agonist

Characterising a molecule that engages three receptors requires, at minimum, three single-receptor assays run in parallel with the matching native ligand as reference, so that each potency is reported against its own baseline rather than against an arbitrary shared scale. Cross-reactivity checks — confirming that a GLP-1R assay line does not also express detectable GIPR or GCGR — are a basic control that is easy to omit and important to report.

Because retatrutide is supplied for research use only, any laboratory generating potency data should also verify the identity and purity of the material used, since an unverified sample introduces a variable that can be mistaken for a pharmacological finding.

Searching the literature efficiently

Because the receptor names are shared with a large pre-existing pharmacology literature, a search combining the receptor name with retatrutide or LY3437943 is more efficient than searching the receptor alone. PubMed and the underlying clinical trial registries are the most reliable primary sources, ahead of secondary summaries that can carry forward transcription errors.

Readers comparing sources should expect the receptor biology to be stable across reviews but the specific potency figures and their reported ratios to vary by paper and by assay format, which is a reason to record which source and assay a given number came from rather than treating figures as universal constants.

Analytical verification underpinning receptor-level claims

Any receptor-level pharmacology result is only as reliable as the material used to generate it. Before a laboratory attributes a signal to the GIP, GLP-1 or glucagon receptor, the test compound should be verified for identity by mass spectrometry and for purity by HPLC, referenced against the batch certificate of analysis, so that an unexpected result can be distinguished from a genuine receptor finding rather than confused with degraded or impure starting material.

This step matters more, not less, for a tri-agonist than for a single-receptor compound, because an unexplained shift in one receptor’s apparent potency could reflect either true differential receptor pharmacology or a material-level problem specific to that assay run, and only documented analytical verification lets a researcher rule the latter out with confidence.

Open questions across the three receptors

Several questions remain open across this receptor set: the exact potency ratio reported for a given batch should always be read from the primary paper or certificate of analysis rather than assumed to be fixed across all supplied material, the functional direction of sustained GIP receptor agonism in intact systems is still debated, and how the three receptors’ signalling interacts in tissues that co-express more than one of them is not fully mapped.

Progress on these questions is most likely to come from studies that vary one receptor’s contribution while holding the other two constant, using receptor-selective comparators and matched assay formats, rather than from further comparisons between unrelated compounds tested under different conditions. Readers tracking this area should expect the picture to be refined as later mechanistic and clinical studies are published.

Strength of the current evidence

Receptor identity is documented in the primary literature. Arm-by-arm contribution in intact systems remains an open research question.

References

1. Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022 (PubMed)
2. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity. NEJM, 2023 (PubMed)
3. Incretin receptor pharmacology literature (GIP, GLP-1, glucagon receptors) (PubMed search listing)

Related Retatrutide research

• GLP-1 Receptor — The GLP-1 receptor: expression, signalling and its role in incretin peptide research.
• GIP Receptor — GIP receptor biology and why GIP activity is included in dual and triple agonist design.
• Glucagon Receptor — Hepatic glucagon receptor signalling and its role in the retatrutide profile.
• Triple Receptor Agonism — What triple receptor agonism means in peptide design, and how balance between receptors is characterised.

Back to the Retatrutide research hub · Retatrutide research material · Certificates of analysis

Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.